Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $805 million, representing a 7.5% increase on a reported basis and a 3.3% increase organically [9][18] - Adjusted EPS for the fourth quarter was $2.04, up 12% compared to the prior year [9][23] - Free cash flow in the fourth quarter was $175 million, more than double the prior year level, contributing to a full year free cash flow of $469 million, up 70% year-on-year [6][24] Business Line Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in the fourth quarter and 9% for the full year of 2025 [10][19] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year organically due to a prior year incentive payment [11][20] - Standard products, which represent 20% of the business, declined 1.7% on an organic basis during the fourth quarter [11][21] - Contract manufacturing revenues increased 1.9% organically in Q4, driven by self-injected devices for obesity and diabetes [11][21] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, as well as increasing global regulatory requirements [7][12] - The Annex 1 upgrades represent a multiyear opportunity with over 700 projects initiated, with more than half completed and generating revenues [14][81] Company Strategy and Development Direction - The company aims to leverage growth drivers such as biologics, Annex 1, and GLP-1s to advance its strategies in 2026 [12][18] - The launch of the West Synchrony Prefillable Syringe System is a significant step in drug delivery solutions, designed specifically for biologics [7][73] - The company is focused on organic growth while considering potential acquisitions that could enhance its high-value product components [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with momentum, expecting organic revenue growth of 5%-7% and adjusted EPS growth of 10% at the midpoint of guidance [18][29] - The company anticipates continued improvement in the injectable market throughout 2026, driven by underlying trends [25][29] Other Important Information - The company expects to close the SmartDose transaction mid-year, which will impact revenue guidance for 2026 [25][26] - Capital expenditures for the year were $286 million, down $91 million year-on-year, with expectations for further reductions in 2026 [24] Q&A Session Questions and Answers Question: Insights on GLP-1 customer demand and guidance conservatism - Management indicated no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength in the business beyond GLP-1s [35][36] Question: Potential for M&A or share buybacks - Management confirmed that capital deployment priorities remain focused on organic growth, but they are open to technologies that could enhance their portfolio [39][40] Question: Demand outstripping supply in HVP components - Management acknowledged that demand continues to outpace supply, with ongoing capacity expansion to meet this demand [42][44] Question: Clarification on GLP-1 growth assumptions - Management noted that GLP-1s grew in excess of 50% in 2025, while non-GLP-1s were roughly flat, with expectations for acceleration in 2026 [78] Question: Details on Annex 1 cycle upgrades - Management highlighted that less than 15% of the 6 billion components opportunity has been commercialized, viewing it as a multiyear journey [14][81]

Financial Data and Key Metrics Changes - The company reported Q4 revenues of $805 million, representing a 7.5% increase year-over-year and a 3.3% organic growth [9][18] - Adjusted EPS for Q4 was $2.04, up 12% compared to the prior year [9][23] - Free cash flow in Q4 was $175 million, more than double the prior year level, contributing to a full-year free cash flow of $469 million, up 70% year-over-year [6][24] Business Segment Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in Q4 and 9% for the full year of 2025 [10][19] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year in Q4 due to a prior year incentive payment [11][20] - Standard products declined 1.7% on an organic basis in Q4, while contract manufacturing revenues increased 1.9% organically [11][21] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, as well as increasing global regulatory requirements [7][12] - The GLP-1 market is expected to continue supporting growth, with the adoption of GLP-1s still in early stages [15][17] Company Strategy and Development Direction - The company aims for 5%-7% organic revenue growth in 2026, with adjusted EPS growth of 10% at the midpoint of guidance [18][29] - A comprehensive evaluation of the SmartDose business led to its sale, aligning with the company's focus on patient-centric approaches for large on-body delivery devices [8] - The company is expanding its capacity in Dublin for drug handling, which is expected to ramp up throughout 2026 [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy, highlighting the effectiveness of their execution and the momentum entering 2026 [6][30] - The company anticipates continued improvement in the injectable market throughout 2026, with a focus on high-value products [25][29] Other Important Information - The company completed 65 Annex 1 projects in Q4 2025, with over 700 projects initiated, indicating strong progress in regulatory compliance [14][80] - The company expects to close the SmartDose transaction mid-year, impacting future revenue guidance [25][29] Q&A Session Summary Question: Insights on GLP-1 customer demand and guidance conservatism - Management noted no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength beyond GLP-1s [35][36] Question: Potential for M&A or share buybacks - Management indicated that while organic growth remains a priority, they are open to exploring technologies that could enhance their high-value product components [39][40] Question: Demand outstripping supply in HVP components - Management confirmed that demand continues to outpace supply, with ongoing capacity expansion to meet this demand [42][44] Question: Clarification on growth assumptions for HVP in 2026 - Management provided ranges indicating GLP-1s grew over 50% in 2025, while non-GLP-1s were roughly flat, expecting acceleration in 2026 [78]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $805 million, representing a 7.5% increase on a reported basis and a 3.3% increase organically [8][17] - Adjusted EPS for the fourth quarter was $2.04, up 12% compared to the prior year [8][22] - Free cash flow in the fourth quarter was $175 million, more than double the prior year level, contributing to a full year free cash flow of $469 million, up 70% year-on-year [8][23] Business Segment Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in the fourth quarter and 9% for the full year of 2025 [9][18] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year organically, primarily due to an incentive payment received in the prior year [10][18] - Standard Products, which represent 20% of the business, declined 1.7% on an organic basis during the fourth quarter [10][18] - Contract manufacturing revenues increased 1.9% organically in Q4, driven by self-injected devices for obesity and diabetes [10][18] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, increasing global regulatory requirements, and the expanding GLP-1 market [5][11] - The company has initiated over 700 Annex 1 projects, with over half completed and generating revenues, representing less than 15% of the 6 billion components targeted for upgrades [12][80] Company Strategy and Development Direction - The company aims to leverage growth drivers such as biologics, Annex 1, and GLP-1s to advance its strategies and expects robust momentum entering 2026 [11][17] - The launch of the West Synchrony Prefillable Syringe System is a significant step in drug delivery solutions, designed specifically for biologics [5][72] - The company plans to continue investing in high-value product components while exploring potential technologies for inorganic growth [39][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy, highlighting a strong order book and demand from biologic customers [42][59] - The company anticipates organic revenue growth of 5%-7% and adjusted EPS growth of 10% at the midpoint for 2026 [17][28] - Management remains cautious about GLP-1 growth, projecting a 10% increase year-on-year, which is considered conservative given the previous year's growth of over 50% [26][76] Other Important Information - The company expects to close the SmartDose transaction mid-year, which will impact revenue guidance for 2026 [24][25] - Capital expenditures for 2026 are expected to decrease to a range of $250 million-$275 million, reflecting a focus on efficiency [23][28] Q&A Session Summary Question: Insights on GLP-1 customer demand and guidance conservatism - Management indicated no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength in the overall business beyond GLP-1s [35][36] Question: Potential for share buybacks or M&A - Management confirmed that capital deployment will prioritize organic growth but remains open to technologies that could enhance the HVP components business [39][40] Question: Demand outstripping supply in HVP components - Management acknowledged that demand continues to outpace supply, particularly in the HVP components business, and is actively expanding capacity [42][43] Question: Clarification on new GLP-1 molecules and HVP components - Management noted that new GLP-1 molecules are expected to use similar elastomeric HVP components, with a mix of new combination molecules requiring proprietary technologies [46][49] Question: Progress on Annex 1 upgrades - Management stated that less than 15% of the 6 billion components have been commercialized, with expectations for continued revenue growth from these projects in 2026 [80]